At the news
? BULLISHIMPACT 6/10 PRESS-RELEASE filed Jun 1, 2026 at 08:00 ET
Immatics reports extended Phase 1b data for anzu-cel (PRAME TCR T-cell therapy) in metastatic melanoma at ASCO 2026, showing 56% confirmed ORR, 14.6-month median DOR, 6.1-month median PFS, and 16.2-month median OS with manageable safety. The Phase 3 SUPRAME trial remains on track with BLA submission expected in 1H 2027.
- 56% confirmed objective response rate (cORR) in heavily pretreated metastatic melanoma (N=33)
- Median duration of response (mDOR) of 14.6 months; median PFS 6.1 months; median OS 16.2 months
- Phase 3 SUPRAME trial advancing; BLA submission targeted for 1H 2027
- Predictable and manageable safety profile with mostly Grade 1-2 CRS and infrequent ICANS
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access